Next Article in Journal
Integrative Analysis of Multi-Omics Data Based on Blockwise Sparse Principal Components
Next Article in Special Issue
Comprehensive Set of Tertiary Complex Structures and Palmitic Acid Binding Provide Molecular Insights into Ligand Design for RXR Isoforms
Previous Article in Journal
Implications of Splicing Alterations in the Onset and Phenotypic Variability of a Family with Subclinical Manifestation of Peutz–Jeghers Syndrome: Bioinformatic and Molecular Evidence
Previous Article in Special Issue
Crystal Structure and Inhibitor Identifications Reveal Targeting Opportunity for the Atypical MAPK Kinase ERK3
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 21
Issue 21
10.3390/ijms21218199
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Chemical Space Exploration of Oxetanes

by
Fernando Rodrigues de Sá Alves
1,
Rafael M. Couñago
2 and
Stefan Laufer
1,3,*
1
Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Faculty of Science, Eberhard Karls University of Tübingen, 72074 Tübingen, Germany
2
Centro de Química Medicinal (CQMED), Centro de Biologia Molecular e Engenharia Genética (CBMEG), Structural Genomics Consortium, Departamento de Genética e Evolução, Instituto de Biologia Universidade Estadual de Campinas (UNICAMP), Campinas 13083-875, SP, Brazil
3
Tübingen Center for Academic Drug Discovery, 72076 Tübingen, Germany
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(21), 8199; https://doi.org/10.3390/ijms21218199
Submission received: 7 October 2020 / Revised: 27 October 2020 / Accepted: 28 October 2020 / Published: 2 November 2020
(This article belongs to the Special Issue Targeting the Untargeted Proteome: From Structure-Based Inhibitor Discovery to Chemical Biology and Beyond)
Browse Figures
Versions Notes

Abstract

:
This paper focuses on new derivatives bearing an oxetane group to extend accessible chemical space for further identification of kinase inhibitors. The ability to modulate kinase activity represents an important therapeutic strategy for the treatment of human illnesses. Known as a nonclassical isoster of the carbonyl group, due to its high polarity and great ability to function as an acceptor of hydrogen bond, oxetane seems to be an attractive and underexplored structural motif in medicinal chemistry.

1. Introduction

Oxetane is a four-membered ring having an oxygen atom with an intrinsic ring strain of 106 kJ.mol−1, which adopts a planar structure with a puckering angle of only 8.7° at 140 K (10.7° at 90 K). The addition of substituents into the oxetane ring can increment unfavorable eclipsing interactions, resulting in a more puckered conformation [1].
The strained C−O−C bond angle exposes the oxygen lone pair of electrons, allowing the oxetane to act as a good hydrogen-bond acceptor as well as donating electron density as a Lewis base. It was also observed experimentally that oxetanes form more effective H-bonds than other cyclic ethers [2]. Similarly, oxetanes compete as H-bond acceptors with the majority of carbonyl functional groups like aliphatic ketones, aldehydes, and esters [3]. These structural features are important for many of the beneficial properties of substituted oxetanes.
Some examples of compounds bearing the oxetane are oxetanocin A, thromboxane A2, mitrephorone A, oxetine and laureatin, as well as the marketed chemotherapy drugs Taxol and Taxotere and a new kinase inhibitor GS-9876 (Figure 1).
In medicinal chemistry, an oxetane group is employed not only to change the conformational preference of the main scaffold but also to influence physicochemical and biochemical properties such as lipophilicity, aqueous solubility, and metabolic stability [4]. Carreira and co-workers from ETH Zurich have been using oxetanes as surrogates of a carbonyl group in order to generate building blocks providing new opportunities of molecular diversity [5,6,7]. The group of Professor Bull from Imperial College London has also been working extensively on the synthesis and new methodologies for obtaining compounds bearing an oxetane [8,9,10]. Recently, Blomgren and co-workers have reported the discovery of a second-generation spleen tyrosine kinase inhibitor, GS-9876 (lanraplenib), which has human pharmacokinetic properties suitable for once-daily administration and it is used against autoimmune diseases [11]. Known as a nonclassical isoster of the carbonyl group [12], due to its high polarity and great ability to function as an acceptor of hydrogen bond, the oxetane still remains an underexplored structural motif in drug discovery, especially in the kinase field, in which the oxetane could bind the “hinge” region (Figure 2). Nevertheless, the conformational variations or the directional hydrogen bonding differences between sp2- and sp3-hybridized oxygen atoms could be a benefit or a drawback for that type of interaction.

2. Results and Discussion

Our main goal was to synthesize new oxetane derivatives to further extend the therapeutical kinase space. We proposed the nonclassical isosteric replacement of the carbonyl group of some kinase inhibitors bearing dibenzosuberone and benzophenone scaffolds by an oxetane moiety (Figure 3). This substitution could lead to an interaction of the oxetane group with the “hinge” region. All protein kinases contain a sequence of amino acids comprising the “hinge” between the two lobes of the catalytic domain. The backbone atoms of the hinge region contain the critical hydrogen bond donor and acceptor atoms anchoring ATP-binding and allowing phosphorylation of the substrate [13].
3,3-disubstituted oxetanes can be readily synthesized from 1,3-diols by conversion of the latter into a halohydrin (or another good leaving group) and then by addition of a strong base to close the ring through an intramolecular Williamson etherification reaction [14,15]. However, in the case of 1,3-diols bearing two aryl groups, an 1,4-elimination process namely Grob fragmentation occurs instead of a cyclization, leading to an alkene [16,17,18]. Thus, a different approach through a catalytic functionalization of tertiary alcohols was used in order to obtain 3,3-diphenyloxetane derivatives (Figure 4).
The ketones 1a–c reacted with dimethylsulfonium methylide in a Corey–Chaykovsky epoxidation reaction [19], leading to the epoxide derivatives 2a–c. In the next step, the aldehydes 3a–c were obtained through a Lewis acid catalyzed epoxide rearrangement by a 1,2-hydride shift, namely Meinwald rearrangement [20]. Then a crossed Cannizzaro reaction was performed [21], reacting the aldehydes with formaldehyde in concentrated basic conditions, obtaining the 1,3-diol derivatives 4a–c. For the synthesis of the oxetanes applying strategy 1, we used the concept of hydroxyl replacement via oxyphosphonium salts, in which phosphonium salts can also be formed by reaction of different trivalent phosphorus compounds with oxidizing electrophiles, like the tris(dimethylamino)phosphine-carbon tetrachloride component system. The produced phosphonium intermediates can be trapped with an alcohol to form alkoxyphosphonium salts, which can then undergo nucleophilic displacement [22]. Based on the works of Castro and Selve [23], the dialkyloxetanes 5a–c were obtained in good yields (Scheme 1).
In the case of (5-chloro-2,3-dihydro-1H-indene-1,1-diyl)dimethanol, as the Corey–Chaykovsky epoxidation reaction did not work, the 5-chloro-indanone 6 was converted in compound 7 through a Wittig reaction [24]. Then a Brown hydroboration reaction was carried out followed by oxidation of the borate, in which the alkene was converted into the primary alcohol 8, using hydrogen peroxide in basic conditions [25,26]. The alcohol 8 was then oxidized to the aldehyde 9 using Dess–Martin periodinane [27] and subsequently converted into the diol 10 and oxetane 11 employing the same reactions mentioned before (Scheme 2).
The 3,3-diaryloxetane scaffold 14 was synthesized based on the works of Croft and co-workers [28] through the catalytic functionalization of a tertiary alcohol to construct a fully substituted carbon center, using Li as a catalyst in a Friedel–Crafts alkylation reaction [29]. A halogen-metal exchange reaction of BuLi and compound 12, followed by a nucleophilic addition of the organolithium to the carbonyl group of the oxetan-3-one, gave rise to compound 13. The 1H NMR spectrum shows two doublets related to the methylene groups of oxetane, at 4.88 and 4.91 ppm. Additionally, the OH group could be detected as a broad singlet at 2.92 ppm. Afterwards, the tertiary alcohol 13 was reacted with phenol, leading to the diaryloxetane 14 in a 60% yield. Compound 14 was then converted into the triflate derivative 15 in a 62% yield [30] (Scheme 3).
For the last step, the optimal experimental conditions were established for the Buchwald–Hartwig reaction of the halide scaffolds with arylamines, using a catalyst system composed of Pd(OAc)2, XPhos and Cs2CO3, in a methodology adapted from our research group for dibenzosuberone derivatives [31]. For the coupling of the aryl triflate with arylamines, a modified method from Buchwald’s group was employed [32,33], through a catalyst system composed of Pd(OAc)2, BINAP and Cs2CO3. No formation of phenol was detected. The deprotection of the benzyloxyl group was carried out with Pd/C under H2 atmosphere at r.t. in a mixture of ethanol/acetonitrile, leading to the final compounds in quantitative yields. The oxetane derivatives were reacted with different arylamines. The 2,4-difluoroaniline was initially selected, based on previous works of our laboratory, where it had demonstrated good potency for some kinase inhibitors [34]. Then other modifications were carried out in the arylamine subunit, selecting both electron-withdrawing and donating groups. Additionally, aniline was chosen as a non-substituted group to complete the design of new derivatives (Table 1).
In order to identify novel scaffolds for molecular recognition in kinases, we selected some compounds to be screened in a panel of kinases using the differential scanning fluorimetry (DSF) method [35,36] at SGC-Unicamp. This technique allows selectivity profiling of any protein kinase without prior knowledge of either substrate or activity of the kinase under investigation. The most promising results were obtained for the CAMK1G calcium/calmodulin dependent protein kinase I gamma and for AAK1 AP2-associated protein kinase 1, as depicted in Figure 5, showing Tm shifts greater than 2 °C. The pankinase inhibitor staurosporine (stauro) served as a positive control in the assay.
4-(3-phenyloxetan-3-yl)phenol derivatives 20c and 20e showed a ΔTm of 5.8 °C and 5.2 °C at 10 µM, respectively against CAMK1G (Figure 6). These results suggest that electron-withdrawing groups on the aryl ring are well tolerated, in which the 4-CF3 and 4-CN analogs showed similar values. However, both an electron-donating group like 4-OCH3 (20d) and the group 2,4-difluoryl (20b) were detrimental to CAMK1G interaction. Calcium–calmodulin dependent protein kinase I (CaMKI) is part of a calmodulin-dependent protein kinase cascade and is implicated in various physiological processes, being expressed in many tissues. CaMKI regulates transcriptional activator activity, the cell cycle, cell differentiation, actin filament organization and neurite outgrowth [37]. However, the role of CAMK1G is still mainly unclear.
Compounds 20c and 19b showed a ΔTm of 5.2 °C and 4.5 °C, respectively against AAK1 (Figure 7). Adaptor-associated kinase 1 (AAK1), a member of Ark1/Prk1 family of serine/threonine kinases, is involved in the endocytic pathway. Although AAK1 has been mostly related to the regulation of receptor endocytosis, several studies suggested that AAK1 may be associated to psychiatric and neurological disorders [38]. Recently, Kostich and co-workers have showed that the inhibition of AAK1 kinase could be a novel therapeutic approach for the treatment of neuropathic pain [39]. The inhibition of AAK1 also showed to be important as an antivirus strategy, especially against HCV [40,41]. In addition to these preliminary results, new structural modifications and experiments to measure the Kd and IC50 will be carried out for a better understanding of the structure-activity relationship.

3. Materials and Methods

All commercially available reagents and solvents were used without further purification. 1H and 13C nuclear magnetic resonance (NMR) spectra were determined in DMSO-d6, CDCl3 and Acetone-d6 solutions using a Bruker Avance 200 (1H = 200 MHz; 13C = 50 MHz) or a Bruker Avance 400 (1H = 400 MHz; 13C = 100 MHz) spectrometer. The chemical shifts are given in parts per million (ppm) from solvent residual peaks and the coupling constant values (J) are given in Hz. Signal multiplicities are represented by: s (singlet), d (doublet), dd (double doublet), t (triplet), m (multiplet) and br (broad signal). The evaluation of spectra was performed using the MestReNova program. Infrared spectra were obtained using a Thermo Scientific Nicolet’s Avatar iS10 spectrometer equipped with a smart endurance diamond ATR unit for direct measurements. ESI mass spectra were obtained from a TLC-MS interface CAMAG in negative mode [M − H+]. EI-MS mass spectra were obtained from the Mass Spectrometry Department of the Institute of Organic Chemistry, University of Tübingen: Finnigan MAT, TSQ 70 Tripel quadrupol; ion source temperature at 200 °C; temperature of evaporation: 30–300 °C; ionization energy: 70 eV. The compounds were purified through column chromatography, using silica gel as stationary phase (Geduran® Si 60, 0.063–0.200 mm). The purity of compounds was determined by HPLC (Merck Hitachi L-6200 intelligent pump, Merck Hitachi AS-2000 auto sampler, Merck Hitachi L-4250 UV vis detector) using a ZORBAX Eclipse XDB C8 column (5 mm), employing a gradient of 0.01 M KH2PO4 (pH 2.3) and methanol as solvent system with a flow rate of 1.5 mL/min and detection at 254 nm.
Kinase selectivity assay: Starting from 100 µM protein stocks, all the kinases present in the panel were diluted to 1 µM in buffer 100 mM K2HPO4 pH 7.5 containing 150 mM NaCl, 10% glycerol and 1X dye (Applied Biosystems catalog 4461806). The protein/dye mixture was transferred column-wise to a 384-well PCR microplate with 20 µL per well. Compounds at 10 mM concentration in DMSO (from a separate plate arranged in rows) were added next, in 20 nL volume, using a liquid handling device setup with a pin head to make a final 10 µM compound in the assay plate. The final DMSO concentration in all wells is 0.2%, including the reference with DMSO only. Thermal shift data was measured in a qPCR instrument (Applied Biosystems QuantStudio 6) programmed to equilibrate the plate at 25 °C for 5 min followed by ramping the temperature to 95 °C at a rate of 0.05 °C per second. Data was processed on Protein Thermal shift software (Applied Biosystems) fitting experimental curves to a Boltzmann function to calculate differential thermal shifts (dTm) referenced to protein/dye in 0.2% DMSO. The kinases were cloned, expressed (bacteria or insect cell expression) and purified at the laboratory of SGC.

3.1. General Procedure A—Corey-Chaykovsky Epoxidation

4.0 eq. of NaH (60% dispersion in mineral oil) was placed in a three-necked flask under argon and then DMSO (0.6 M) and the ketone were added, after which 2.25 eq. of trimethylsulfonium iodide was also added, all at once. The reaction mixture was stirred at ambient temperature. After controlling through TLC, the mixture was poured over ice and extracted with diethyl ether and ethyl acetate (1:1). The extracts were combined, washed with brine and afterwards dried over Na2SO4. The solvent was removed under vacuum, and the residue was used without purification for the next step. Adapted from Winter [19].
2-bromo-6,7,8,9-tetrahydrospiro[benzo[7]annulene-5,2′-oxirane] (2a): Yellow oil. 95% yield. 1H-NMR (200 MHz, CDCl3) δ in ppm: 1.62–1.80 (m, 2H), 1.80–2.15 (m, 2H), 2.74 (d, 1H, J = 6.0 Hz), 2.82–2.87 (m, 2H), 2.98 (d, 1H, J = 6.0 Hz), 7.30 (m, 3H); 13C-NMR (50 MHz, CDCl3) δ in ppm: 27.0, 28.6, 35.9, 36.0, 53.9, 60.8, 121.2, 126.9, 129.1, 131.8, 140.1, 143.3.
6-bromo-3,4-dihydro-2H-spiro[naphthalene-1,2′-oxirane] (2b): Yellow solid. 90% yield. 1H-NMR (200 MHz, CDCl3) δ in ppm: 1.75–1.85 (m, 2H), 2.06–2.11 (m, 2H), 2.83–2.87 (m, 2H), 2.97 (s, 2H), 6.92–6.96 (d, 2H), 7.27–7.29 (s, 1H); 13C-NMR (50 MHz, CDCl3) δ in ppm: 21.9, 29.6, 31.7, 56.4, 58.9, 121.5, 125.4, 129.6, 131.4, 134.9, 141.7.
2-(4-bromophenyl)-2-methyloxirane (2c): Yellow solid. 90% yield. 1H-NMR (200 MHz, CDCl3) δ in ppm: 1.70 (s, 3H), 2.74–2.77 (d, 1H), 2.97–2.99 (d, 1H), 7.22–7.26 (d, J = 8.0 Hz, 2H), 7.44–7.48 (d, J = 8.0 Hz, 2H); 13C-NMR (50 MHz, CDCl3) δ in ppm: 21.7, 56.5, 57.1, 121.6, 127.2, 131.6, 140.4.

3.2. General Procedure B—Meinwald Rearrangement

The crude epoxide was dissolved in benzene (0.3 M) and 0.3 eq. of ZnI2 was added; the reaction mixture was heated at reflux under argon. After controlling through TLC, it was then diluted with ethyl acetate and washed with water. The organic layer was dried with Na2SO4, and the solvent was evaporated to afford the pure aldehyde, which was used without purification for the next step. Adapted from Snyder et al. [20].
2-bromo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-carbaldehyde (3a): Brown oil. 98% yield. 1H-NMR (200 MHz, CDCl3) δ in ppm: 1.59–2.25 (m, 6H, CH2), 2.68 (t, 2H, CH2), 3.71 (d, 1H, CH), 6.95 (d, 1H, J = 8.0 Hz), 7.31 (m, 2H), 9.89 (s, 1H).
6-bromo-1,2,3,4-tetrahydronaphthalene-1-carbaldehyde (3b): Brown oil. 95% yield. 1H-NMR (200 MHz, CDCl3) δ in ppm: 1.92 (m, 2H), 2.24 (m, 2H), 2.72–2.78 (t, 2H), 3.58 (t, 1H), 6.99–7.03 (d, 1H), 7.30–7.34 (m, 2H), 9.64 (s, 1H); 13C-NMR (50 MHz, CDCl3) δ in ppm: 20.2, 22.9, 29.1, 51.3, 121.2, 129.4, 129.9, 131.3, 132.6, 140.3, 201.4.
2-(4-bromophenyl)propanal (3c): Brown oil. 98% yield. 1H-NMR (200 MHz, CDCl3) δ in ppm: 1.41–1.45 (d, 3H), 3.55–3.66 (q, 1H), 7.06–7.11 (d, 2H), 7.48–7.52 (d, 2H), 9.65 (s, 1H); 13C-NMR (50 MHz, CDCl3) δ in ppm: 14.7, 52.5, 121.7, 130.1, 132.3, 136.8, 200.5.

3.3. General Procedure C—Crossed Cannizzaro Reaction

A mixture of 35% formalin, KOH 50% aqueous solution and the aldehyde in ethylene glycol (0.4 M) was heated at reflux overnight. Water was added to the resulting mixture, and the organic layer was extracted with CH2Cl2, washed with brine, and dried over Na2SO4. After concentration of the solution, hexane was added immediately with vigorous stirring, and then the mixture was cooled to 0 °C. White precipitate was collected, washed with hexane, and dried under air to obtain the diol. Adapted from Sato et al. [21].
(2-bromo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-5,5-diyl)dimethanol (4a): White solid. 61% yield. HPLC: 6.948 min (83%) at 254 nm. IR (ATR): 3276, 2931, 2882, 2855, 1556, 1445 cm−1. ESI-MS: Calculated: 284.0 for C13H17BrO2. Found: 283 [M − H]−. 1H-NMR (200 MHz, CDCl3) δ in ppm: 1.26 (s, 2H, CH2), 1.79 (m, 4H, CH2), 2.31 (s, 2H, CH2), 2.90 (br, 2H), 3.88 (d, 2H, J = 10 Hz), 4.04 (d, 2H, J = 12 Hz), 7.27–7.30 (m, 3H); 13C-NMR (50 MHz, CDCl3) δ in ppm: 23.9, 27.3, 30.9, 35.9, 48.6, 68.5, 120.7, 129.3, 129.9, 134.4, 140.2, 144.8.
(6-bromo-1,2,3,4-tetrahydronaphthalene-1,1-diyl)dimethanol (4b): White solid. 45% yield. HPLC: 6.950 min (96%). IR (ATR): 3269, 2928, 2868, 2360, 1479 cm−1. ESI-MS: Calculated: 270.03 for C12H15BrO2. Found: 269 [M − H]−. 1H-NMR (200 MHz, CDCl3) δ in ppm: 1.77–1.92 (m, 4H), 1.93 (s, 2H), 2.72–2.78 (t, 2H), 3.71–3.76 (d, 2H, J = 10 Hz), 3.87–3.92 (d, 2H, J = 10 Hz), 7.27 (s, 3H); 13C-NMR (50 MHz, CDCl3) δ in ppm: 18.9, 27.7, 30.5, 43.3, 69.7, 120.6, 128.9, 129.2, 132.4, 136.9, 141.2.
(5-chloro-2,3-dihydro-1H-indene-1,1-diyl)dimethanol (10): White solid. 30% yield. HPLC: 5.580 min (98%). IR (ATR): 3280, 2933, 2877, 2843, 1451, 1200, 824 cm−1. ESI-MS: Calculated: 212.0 for C11H13ClO2. Found: 211 [M − H]−. 1H-NMR (200 MHz, CDCl3) δ in ppm: 2.04–2.12 (m, 4H), 2.88–2.96 (t, 2H), 3.72–3.87 (q, 4H), 7.12–7.25 (m, 3H); 13C-NMR (50 MHz, CDCl3) δ in ppm: 30.2, 31.4, 54.2, 68.2, 125.2, 125.4, 126.8, 133.6, 143.2, 146.8.
2-(4-bromophenyl)-2-methylpropane-1,3-diol (4c): White solid. 67% yield. HPLC: 5.280 min (100%). ESI-MS: Calculated: 244.01/246.01 for C10H13BrO2. Found: 243/245 [M − H]−. 1H-NMR (200 MHz, CDCl3) δ in ppm: 1.25 (s, 3H), 2.22 (s, 2H), 3.78–3.83 (d, 2H), 3.91–3.97 (d, 2H), 7.29–7.33 (d, 2H), 7.46–7.51 (d, 2H); 13C-NMR (50 MHz, CDCl3) δ in ppm: 20.9, 44.5, 70.0, 120.8, 128.7, 131.8, 142.3.

3.4. General Procedure D—Wittig Reaction

Methyltriphenylphosphonium bromide (1.287 g, 3.601 mmol) was suspended in 15 mL of dry THF at 0 °C. KOtBu (0.404 g, 3.601 mmol) was added to the suspension and a bright yellow color was observed. The mixture was stirred at 0 °C for 30 min. Then 5-chloro-2,3-dihydro-1H-inden-1-one (0.200 g, 1.200 mmol) was added neat and the reaction mixture was stirred at 0 °C to r.t. for 4 h (the solution turned green and then dark brown). Water was added to the mixture and the product was extracted with CH2Cl2 and dried with Na2SO4, filtrated and concentrated in vacuum. The residue was purified by column chromatography using n-hexane. Adapted from Liwosz and Chemler [24].
5-chloro-1-methylene-2,3-dihydro-1H-indene (7): Incolor oil. 83% yield. HPLC: 9.720 min (99.4%). 1H-NMR (200 MHz, CDCl3) δ in ppm: 2.77–2.85 (m, 2H), 2.93–3.00 (m, 2H), 5.04–5.07 (t, 1H), 5.42–5.44 (t, 1H), 7.15–7.19 (d, J = 8.0 Hz, 1H), 7.23 (s, 1H), 7.38–7.42 (d, J = 8.0 Hz, 1H); 13C-NMR (50 MHz, CDCl3) δ in ppm: 13.1, 37.6, 119.7, 124.1, 126.3, 129.2, 130.7, 139.5, 144.8, 146.1.

3.5. General Procedure E—Brown Hydroboration—Oxidation

A solution of 1.6 g (9.537 mmol) of 5-chloro-1-methylene-2,3-dihydro-1H-indene in 10 mL of THF was treated with a solution of 19.0 mL of BH3-THF complex at ice-bath temperature. The reaction mixture was stirred until disappearance of the alkene. It was then cooled in a water-ice bath, and carefully treated with methanol followed by addition of 31.8 mL (95.365 mmol) of NaOH 3.0 M and 25.3 mL (247.959 mmol) of 30% H2O2. The resulting mixture was stirred at room temperature, poured into water, acidified with 10% HCl, and extracted with ether. The organic layer was dried with Na2SO4 and the solvent was evaporated to afford the pure alcohol after purification by column in silica gel (20% EtOAc:n-hexane). Adapted from Zimmerman and Nesterov [26].
(5-chloro-2,3-dihydro-1H-inden-1-yl)methanol (8): Yellow oil. 80% yield. HPLC: 9.720 min (99.4%). IR (ATR): 3323, 2940, 2866, 1598, 1471, 1067, 870 cm−1. 1H-NMR (400 MHz, CDCl3) δ in ppm: 1.62 (br s, 1H), 1.91–1.98 (sextet, 1H), 2.23–2.32 (sextet, 1H), 2.82–2.99 (m, 2H), 3.27–3.34 (quintet, 1H), 3.76–3.77 (d, 2H), 7.13–7.15 (d, 1H), 7.19–7.21 (m, 2H); 13C-NMR (50 MHz, CDCl3) δ in ppm: 28.7, 31.4, 47.1, 65.9, 125.1, 125.3, 126.5, 132.8, 142.5, 146.8.

3.6. General Procedure F—Dess–Martin Reaction

To a solution of 0.470 g (2.573 mmol) of (5-chloro-2,3-dihydro-1H-inden-1-yl)methanol in 20 mL of CH2Cl2 (0.13 M) 1.6 g (3.860 mmol) of Dess–Martin periodate was added. The reaction was allowed to stir at room temperature for 3 h. TLC and HPLC analysis showed formation of the desired product. The solution was diluted with CH2Cl2 and a 10% Na2S2O3 solution to consume the excess Dess–Martin reagent was added. The mixture was stirred until the two layers separated. The CH2Cl2 layer was collected, washed with saturated Na2CO3 solution and dried with Na2SO4, filtered and evaporated to give the crude aldehyde, which was used in the next step without purification. Adapted from Thongsornkleeb and Danheiser [27].
5-chloro-2,3-dihydro-1H-indene-1-carbaldehyde (9): Yellow oil. 98% yield. 1H-NMR (200 MHz, CDCl3) δ in ppm: 2.36–2.45 (m, 2H), 2.95–3.03 (t, 2H), 3.88–3.95 (t, 1H), 7.20 (s, 3H), 9.64 (s, 1H); 13C-NMR (50 MHz, CDCl3) δ in ppm: 25.8, 31.7, 57.3, 125.5, 126.0, 127.1, 134.0, 137.0, 146.8, 200.2.

3.7. General Procedure G—Nucleophilic Addition to the Carbonyl Group

Compound 9 was synthesized according to General Procedure H: 2,6 mL (6.513 mmol) of n-BuLi was added dropwise over 5 min to a solution of 1.71 g (6.513 mmol) of 1-(benzyloxy)-4-bromobenzene in 20 mL of THF at −78 °C. The reaction mixture was stirred at −78 °C for a further 30 min. Then, 0.36 g (5.010 mmol) of oxetan-3-one was added dropwise to the reaction mixture. After a further 45 min at −78 °C the reaction mixture was warmed to room temperature then quenched with water. The layers were separated and the aqueous portion extracted with diethylether. The organic extracts were combined, washed with brine, dried over Na2SO4, filtered and concentrated in vacuum. Purification by column chromatography (40% EtOAc:n-hexane) afforded the product. Adapted from Croft et al. [28].
3-(4-(benzyloxy)phenyl)oxetan-3-ol (13): White solid. 70% yield. HPLC: 6.898 min (98%). 1H-NMR (400 MHz, CDCl3) δ in ppm: 2.92 (br, 1H), 4.86–4.91 (m, 4H), 5.09 (s, 2H), 7.00–7.02 (d, 2H, J = 8.0 Hz), 7.33–7.35 (d, 2H, J = 8.0 Hz), 7.38–7.45 (m, 4H), 7.47–7.49 (d,2H, J = 8.0 Hz); 13C-NMR (100 MHz, CDCl3) δ in ppm: 70.2, 75.8, 85.7, 115.2, 126.1, 127.6, 128.2, 128.8, 134.9, 136.9, 158.6.

3.8. General Procedure H—Oxetane Formation via Williamson Etherification

The diol was dissolved in THF (0.1 M) and then 4 eq. of CCl4 was added. The solution was cooled to −48 °C and then 1.1 eq. of Tris(dimethylamino)phosphine in 1 mL of THF was added slowly to this solution during 5 min. The solution turned slightly turbid. The flask was transferred to an ice-bath and then agitated until it reached room temperature. After controlling using HPLC, the solvent was evaporated and then methanol was added followed by 4 eq. of a 5.4 M solution of sodium methoxide. The mixture was refluxed at 90 °C during 1 h. The reaction was then diluted with ethyl acetate and washed with water. The organic layer was dried with Na2SO4 and the solvent was evaporated to afford a product after purification by column in silica gel (5% EtOAc: n-hexane). Adapted from Castro and Selve [23].
2-bromo-6,7,8,9-tetrahydrospiro[benzo[7]annulene-5,3′-oxetane] (5a): Yellow oil. 47% yield. HPLC: 8.497 min (93%). EI-MS: Calculated 266.03 for C13H15BrO. Found: 235.9 [M-CH2O]+●. 1H-NMR (200 MHz, CDCl3) δ in ppm: 1.53–1.59 (t, 2H), 1.99–2.01 (t, 2H), 2.12–2.15 (d, 2H), 2.4–2.45 (d, 2H), 4.70–4.73 (d, J = 6.0 Hz, 2H), 4.97–5.00 (d, J = 6.0 Hz, 2H), 6.92–6.96 (d, 1H), 7.21–7.33 (m, 2H). 13C-NMR (50 MHz, CDCl3) δ in ppm: 26.4, 26.9, 34.9, 36.5, 47.9, 80.4, 120.0, 129.2, 132.5, 143.4, 144.4.
6-bromo-3,4-dihydro-2H-spiro[naphthalene-1,3′-oxetane] (5b): Yellow oil. 48% yield. HPLC: 8.230 min (98%). EI-MS: Calculated 252.01 for C12H13BrO. Found: 221.9 [M-CH2O]+●. 1H-NMR (200 MHz, CDCl3) δ in ppm: 1.65–1.77 (m, 2H), 2.14–2.20 (t, 2H), 2.69–2.75 (t, 2H), 4.62–4.65 (d, J = 6.0 Hz, 2H), 4.75–4.78 (d, J = 6.0 Hz, 2H), 7.21–7.22 (s, 1H), 7.38–7.43 (d, 1H), 7.77–7.81 (d, 1H). 13C-NMR (50 MHz, CDCl3) δ in ppm: 20.0, 29.9, 35.3, 42.2, 85.4, 120.4, 128.4, 129.9, 131.7, 138.7, 139.2.
5-chloro-2,3-dihydrospiro[indene-1,3′-oxetane] (11): Yellow oil. 47% yield. HPLC: 7.664 min (97%). EI-MS: Calculated 194.0 for C11H11ClO. Found: 163.9 [M-CH2O]+●. 1H-NMR (200 MHz, CDCl3) δ in ppm: 2.43–2.50 (t, J = 6.0 Hz, 2H), 2.83–2.90 (t, J = 6.0 Hz, 2H), 4.80 (s, 4H), 7.17 (s, 1H), 7.18–7.29 (d, 1H), 7.56–7.60 (d, 1H). 13C-NMR (50 MHz, CDCl3) δ in ppm: 30.4, 37.9, 50.9, 84.2, 123.8, 124.8, 127.4, 133.4, 144.7, 145.4.
3-(4-bromophenyl)-3-methyloxetane (5c): Yellow solid. 35% yield. HPLC: 7.390 min (98%). EI-MS: Calculated 226.00 for C10H11BrO. Found: 195.9 [M-CH2O]+●. 1H-NMR (200 MHz, CDCl3) δ in ppm: 1.71 (s, 3H), 4.62–4.64 (d, 2H), 4.90–4.93 (d, 2H), 7.07–7.11 (d, J = 8.0 Hz, 2H), 7.46–7.50 (d, J = 8.0 Hz, 2H). 13C-NMR (50 MHz, CDCl3) δ in ppm: 27.7, 43.3, 83.64, 120.3, 127.0, 131.8, 145.6.

3.9. General Procedure I—Oxetane Formation via Friedel-Crafts Reaction

Quantities of 0.008 g (0.028 mmol) of lithium bis(trifluoromethanesulfonimide) and 0.006 g (0.014 mmol) of tetrabutylammonium hexafluorophosphate were added to a solution of 0.066 g (0.258 mmol) of 3-(4-(benzyloxy)phenyl)oxetan-3-ol and 0.12 g (1.288 mmol) of phenol in 0.5 mL of chloroform. The reaction mixture was stirred at 40 °C for 1 h then quenched with sat. aq. NaHCO3. CH2Cl2 was added and the layers were separated. The organic extracts were combined, dried over Na2SO4, filtered and concentrated in vacuum. Purification by column chromatography (30% EtOAc:n-hexane) afforded the oxetane. Adapted from Croft et al. [28].
4-(3-(4-(benzyloxy)phenyl)oxetan-3-yl)phenol (14): White solid. 60% yield. HPLC: 8.286 min (93%). ESI-MS: Calculated: 332.14 for C22H20O3. Found: 331.1 [M − H]−. 1H-NMR (200 MHz, CDCl3) δ in ppm: 5.06 (s, 2H), 5.21 (s, 4H), 6.78–6.82 (d, J = 8.0 Hz, 2H), 6.94–6.98 (d, J = 8.0 Hz, 2H), 7.05–7.15 (m, 4H), 7.36–7.42 (m, 5H); 13C-NMR (50 MHz, CDCl3) δ in ppm: 50.5, 70.2, 85.2, 114.9, 115.5, 127.6, 127.8, 127.9, 128.2, 128.8, 137.1, 138.3, 138.5, 154.4, 157.6.

3.10. General Procedure J—Triflate Formation

First, 0.2 mL (2.708 mmol) of pyridine, then 0.3 mL (2.031 mmol) of triflic anhydride were added to a solution of 4-(3-(4-(benzyloxy)phenyl)oxetan-3-yl)phenol in 3.0 mL of CH2Cl2. The reaction mixture was stirred at room temperature. After controlling through TLC and HPLC, the work-up was done adding water followed by CH2Cl2. The layers were separated and the aqueous portion was extracted with CH2Cl2. The organic extracts were combined, dried over Na2SO4, filtered and concentrated in vacuum. Purification by column chromatography (20% EtOAc:n-hexane) afforded the triflate. Adapted from Thompson et al. [30].
4-(3-(4-(benzyloxy)phenyl)oxetan-3-yl)phenyl trifluoromethanesulfonate (15): White solid. 90% yield. HPLC: 10.332 min (100%). ESI-MS: Calculated: 464.09 for C23H19F3O5S. Found: 463.0 [M − H]−. 1H-NMR (200 MHz, CDCl3) δ in ppm: 5.06 (s, 2H), 5.21 (s, 4H), 6.78–6.82 (d, J = 8.0 Hz, 2H), 6.94–6.98 (d, J = 8.0 Hz, 2H),7.05–7.15 (m, 4H), 7.36–7.42 (m, 5H).

3.11. General Procedure K—Buchwald-Hartwig Reaction via Halides

A mixture of 1.0 eq. of aryl halide, 1.0 eq. of amine, 3.0 eq. of Cs2CO3 as the base, 0.5 eq. of X-Phos as the ligand and 0.1 eq. of Pd(OAc)2 as the catalyst in dry 1,4-dioxane and absolute tert-butanol (4:1) (0.05 M) was stirred at reflux under atmosphere of argon. After controlling through TLC and HPLC, the mixture was allowed to cool to room temperature. It was diluted with water and subsequently extracted with ethyl acetate. The extracts were combined, washed with brine and afterwards dried over Na2SO4. The solvent was removed under vacuum, and the residue was purified by column chromatography, affording the desired product. Adapted from Martz et al. [31].
N-phenyl-6,7,8,9-tetrahydrospiro[benzo[7]annulene-5,3′-oxetan]-2-amine (16a): Brown solid. 86% yield. HPLC: 9.015 min (96%). ESI-MS: Calculated: 279.1 for C19H21NO. Found: 278.0 [M − H]−. 1H-NMR (400 MHz, CDCl3) δ in ppm: 1.59 (m, 2H, CH2), 2.01 (m, 2H, CH2), 2.18 (t, 2H, J = 8.0 Hz, CH2), 2.42 (t, 2H, J = 8.0 Hz, CH2), 4.73 (d, 2H), 5.04 (d, 2H), 5.78 (br, 1H), 6.82 (s, 1H), 6.91–7.00 (m, 3H), 7.08 (d, 2H, J = 8.0 Hz),7.27 (t, 2H, J = 8.0 Hz); 13C-NMR (100 MHz, CDCl3) δ in ppm: 26.5, 27.3, 35.5, 37.1, 47.7, 80.7, 115.1, 117.9, 119.4, 121.0,126.2, 129.5, 137.1, 141.8, 143.4.
N-(2,4-difluorophenyl)-6,7,8,9-tetrahydrospiro[benzo[7]annulene-5,3′-oxetan]-2-amine (16b): Brown solid. 73% yield. HPLC: 8.542 min (98%). ESI-MS: Calculated: 315.1 for C19H19F2NO. Found: 314.2 [M − H]−. 1H-NMR (400 MHz, CDCl3) δ in ppm: 1.49 (m, 2H), 1.91 (m, 2H), 2.08 (t, 2H), 2.31 (t, 2H), 4.63–4.64 (d, 2H, J = 4.0 Hz), 4.93–4.94 (d, 2H, J = 4.0 Hz), 5.46 (br, 1H), 6.66 (s, 1H), 6.70–6.82 (m, 3H), 6.89 (d, 1H, J = 8.0 Hz), 7.18 (s, 1H); 13C-NMR (100 MHz, CDCl3) δ in ppm: 26.5, 27.3, 37.1, 47.7, 80.7, 104.1 (dd, J1 = 23.6 Hz, J2 = 23.7 Hz), 110.9 (dd, J1 = 3.64 Hz, J2 = 3.71 Hz), 114.9, 119.3, 119.5 (dd, J1 = 2.28 Hz, J2 = 3.17 Hz), 126.4, 127.9 (dd, J1 = 2.35 Hz, J2 = 2.36 Hz), 137.6, 141.4, 143.6.
N-(2-(trifluoromethyl)phenyl)-6,7,8,9-tetrahydrospiro[benzo[7]annulene-5,3′-oxetan]-2-amine (16c): Yellow solid. 77% yield. HPLC: 10.008 min (96%). ESI-MS: Calculated: 347.1 for C20H20F3NO. Found: 346.1 [M − H]−. 1H-NMR (400 MHz, CDCl3) δ in ppm: 1.58 (m, 2H), 1.99 (m, 2H), 2.17 (t, 2H), 2.42 (t, 2H), 4.73 (d, 2H), 5.02 (d, 2H), 6.02 (br, 1H), 6.84 (s, 1H), 6.90–6.96 (m, 2H), 7.01 (d, 1H, J = 8.0 Hz), 7.32–7.39 (m, 2H), 7.54 (d, 1H, J = 8.0 Hz); 13C-NMR (100 MHz, CDCl3) δ in ppm: 26.5, 27.2, 35.4, 36.9, 47.8, 80.7, 117.2, 117.5, 117.7 (d, J = 10.6 Hz), 119.6, 122.0, 123.6, 126.4, 127.0 (dd, J1 = 5.5 Hz, J2 = 5.4 Hz), 132.8, 139.0, 140.1, 142.5, 143.7.
N-(4-methoxyphenyl)-6,7,8,9-tetrahydrospiro[benzo[7]annulene-5,3′-oxetan]-2-amine (16d): Yellow solid. 86% yield. HPLC: 7.976 min (98%). ESI-MS: Calculated: 309.1 for C20H23NO2. Found: 308.0 [M − H]−. 1H-NMR (200 MHz, CDCl3) δ in ppm: 1.58 (m, 2H), 1.98 (m, 2H), 2.17 (t, 2H), 2.43 (t, 2H), 3.80 (s, 3H), 4.67 (d, 2H, J = 6.0 Hz), 4.99 (d, 2H, J = 6.0 Hz), 5.45 (br, 1H), 6.63–6.74 (m, 3H), 6.84–6.93 (m, 3H), 7.04 (t, 2H); 13C-NMR (100 MHz, CDCl3) δ in ppm: 26.6, 27.3, 35.6, 37.2, 47.9, 55.7, 112.8, 114.8, 117.3, 122.2, 126.2, 135.6, 136.0, 143.3, 143.9, 155.4.
N-phenyl-3,4-dihydro-2H-spiro[naphthalene-1,3′-oxetan]-6-amine (17a): Brown solid. 92% yield. HPLC: 7.967 min (97%). ESI-MS: Calculated: 265.1 for C18H19NO. Found: 264.0 [M − H]−. 1H-NMR (200 MHz, CDCl3) δ in ppm: 1.75–1.84 (m, 2H), 2.24 (t, 2H, J = 6.0 Hz), 2.75 (t, 2H, J = 6.0 Hz), 4.66 (d, 2H, J = 6.0 Hz), 4.87 (d, 2H, J = 6.0 Hz), 6.84 (s, 1H), 6.94–7.10 (m, 4H), 7.33 (t, 2H), 7.83 (d, 2H, J = 8.0 Hz); 13C-NMR (50 MHz, CDCl3) δ in ppm: 20.3, 30.4, 35.9, 42.1, 85.8, 116.8, 117.4, 117.9, 121.1, 127.7, 129.5, 132.1, 138.1, 141.7, 143.2.
N-(2,4-difluorophenyl)-3,4-dihydro-2H-spiro[naphthalene-1,3′-oxetan]-6-amine (17b): Brown solid. 51% yield. HPLC: 8.586 min (98%). ESI-MS: Calculated: 301.1 for C18H17F2NO. Found: 299.9 [M − H]−. 1H-NMR (200 MHz, CDCl3) δ in ppm: 1.70–1.79 (m, 2H), 2.19 (t, 2H, J = 6.0 Hz), 2.70 (t, 2H, J = 6.0 Hz), 4.61 (d, 2H, J = 6.0 Hz), 4.80 (d, 2H, J = 6.0 Hz), 6.70–6.99 (m, 4H), 7.19–7.31 (m, 1H), 7.79 (d, 2H, J = 10 Hz); 13C-NMR (50 MHz, CDCl3) δ in ppm: 20.3, 30.4, 35.8, 42.1, 85.8, 103.9 (dd, J1 = 23.5 Hz, J2 = 23.5 Hz), 110.8 (dd, J1 = 3.76 Hz, J2 = 3.79 Hz), 116.5, 117.3, 119.6 (dd, J1 = 3.22 Hz, J2 = 3.30 Hz), 127.9, 132.7, 138.3, 141.3, 151.0 (d, J = 11.8 Hz), 154.5 (d, J = 11.1 Hz), 155.9 (d, J = 11.8 Hz), 159.3 (d, J = 11.3 Hz).
N-(2-(trifluoromethyl)phenyl)-3,4-dihydro-2H-spiro[naphthalene-1,3′-oxetan]-6-amine (17c): White solid. 82% yield. HPLC: 9.943 min (98%). ESI-MS: Calculated: 333.1 for C19H18F3NO. Found: 332.2 [M − H]−. 1H-NMR (200 MHz, CDCl3) δ in ppm: 1.71–1.74 (m, 2H), 2.20 (t, 2H, J = 6.0 Hz), 2.72 (t, 2H, J = 6.0 Hz), 4.63 (d, 2H, J = 6.0 Hz), 4.82 (d, 2H, J = 6.0 Hz), 6.03 (br, 1H), 6.83 (s, 1H), 6.94 (t, 1H, J = 8.0 Hz), 7.06 (d, 1H, J = 8.0 Hz), 7.32–7.43 (m, 2H), 7.54 (d, 1H, J = 8.0 Hz), 7.84 (d, 1H, J = 8.0 Hz); 13C-NMR (50 MHz, CDCl3) δ in ppm: 20.3, 30.3, 35.8, 42.2, 85.8, 117.3, 117.9, 118.0, 118.9, 119.8, 120.1, 126.9 (dd, J1 = 5.5 Hz, J2 = 5.5 Hz), 127.9, 132.7, 134.1, 138.3, 140.1, 142.2.
N-(2-methoxyphenyl)-3,4-dihydro-2H-spiro[naphthalene-1,3′-oxetan]-6-amine (17d): Yellow solid. 82% yield. HPLC: 9.221 min (95%). ESI-MS: Calculated: 295.1 for C19H21NO2. Found: 294.4 [M − H]−. 1H-NMR (200 MHz, CDCl3) δ in ppm: 1.72–1.83 (m, 2H), 2.24 (t, 2H, J = 6.0 Hz), 2.76 (t, 2H, J = 6.0 Hz), 3.93 (s, 3H), 4.66 (d, 2H, J = 6.0 Hz), 4.87 (d, 2H, J = 6.0 Hz), 6.92 (m, 4H), 7.13 (d, 1H), 7.32 (m, 1H), 7.84 (d, 1H, J = 8.0 Hz); 13C-NMR (50 MHz, CDCl3) δ in ppm: 20.4, 30.4, 35.9, 42.1, 55.7, 85.8, 110.7, 114.9, 117.5, 118.2, 120.0, 120.9, 127.7, 132.3, 133.0, 138.0, 141.3, 148.4.
N-phenyl-2,3-dihydrospiro[indene-1,3′-oxetan]-5-amine (18a): Brown solid. 71% yield. HPLC: 8.231 min (95%). ESI-MS: Calculated: 251.1 for C17H17NO. Found: 250.1 [M − H]−. 1H-NMR (200 MHz, CDCl3) δ in ppm: 2.52 (t, 2H, J = 8.0 Hz), 2.89 (d, 2H, J = 8.0 Hz), 4.83–4.92 (m, 4H), 5.82 (br, 1H), 6.94–7.12 (m, 5H), 7.28–7.36 (m, 2H), 7.57 (d, 2H, J = 8.0 Hz); 13C-NMR (50 MHz, CDCl3) δ in ppm: 30.6, 38.4, 50.9, 84.6, 113.8, 117.4, 177.9, 121.1, 123.6, 129.5, 138.8, 143.0, 143.5, 144.9.
N-(2,4-difluorophenyl)-2,3-dihydrospiro[indene-1,3′-oxetan]-5-amine (18b): Brown solid. 76% yield. HPLC: 8.670 min (100%). ESI-MS: Calculated: 287.1 for C17H15F2NO. Found: 286.1 [M − H]−. 1H-NMR (200 MHz, CDCl3) δ in ppm: 2.47 (t, 2H, J = 6.0 Hz), 2.89 (d, 2H, J = 6.0 Hz), 4.79–4.87 (m, 4H), 6.76–6.98 (m, 4H), 7.17–7.29 (m, 1H), 7.53 (d, 2H, J = 8.0 Hz); 13C-NMR (100 MHz, CDCl3) δ in ppm: 30.6, 38.3, 50.9, 84.6, 103.9, 104.4 (J = 2.87 Hz), 110.8 (J1 = 3.83, J2 = 3.97 Hz), 113.6, 117.3, 119.6 (J1 = 2.86, J2 = 3.34 Hz), 123.7, 139.3, 142.7, 145.1.
N-(2-(trifluoromethyl)phenyl)-2,3-dihydrospiro[indene-1,3′-oxetan]-5-amine (18c): White solid. 95% yield. HPLC: 9.588 min (100%). ESI-MS: Calculated: 319.1 for C18H16F3NO. Found: 318.1 [M − H]−. 1H-NMR (200 MHz, CDCl3) δ in ppm: 2.49 (t, 2H, J = 8.0 Hz), 2.86 (d, 2H, J = 8.0 Hz), 4.80–4.88 (m, 4H), 6.06 (br, 1H), 6.90–6.97 (m, 2H), 7.04 (d, 2H, J = 8.0 Hz), 7.29–7.41 (m, 2H), 7.58 (t, 2H, J = 8.0 Hz); 13C-NMR (50 MHz, CDCl3) δ in ppm: 30.6, 38.2, 50.9, 84.5, 116.5, 117.9, 119.8, 123.7, 127.1, 132.8, 140.7, 141.4, 142.5, 145.1.
N-(2-methoxyphenyl)-2,3-dihydrospiro[indene-1,3′-oxetan]-5-amine (18d): Yellow solid. 80% yield. HPLC: 8.718 min (98%). ESI-MS: Calculated: 281.1 for C18H19NO2. Found: 280.1 [M − H]−. 1H-NMR (200 MHz, CDCl3) δ in ppm: 2.48 (t, 2H, J = 8.0 Hz), 2.86 (d, 2H, J = 8.0 Hz), 3.89 (s, 3H), 4.79–4.89 (m, 4H), 6.15 (br, 1H), 6.85–6.91 (m, 3H), 7.02 (s, 1H), 7.07 (d, 1H), 7.28 (m, 1H), 7.54 (d, 2H, J = 8.0 Hz); 13C-NMR (50 MHz, CDCl3) δ in ppm: 30.6, 38.4, 50.9, 55.7, 84.6, 110.6, 114.5, 114.8, 118.1, 119.9, 120.9, 123.5, 133.3, 138.9, 142.6, 144.8, 148.3.
4-(3-methyloxetan-3-yl)-N-phenylaniline (19a): Brown solid. 83% yield. HPLC: 7.967 min (96%). ESI-MS: Calculated: 239.1 for C16H17NO. Found: 238.0 [M − H]−. 1H-NMR (400 MHz, CDCl3) δ in ppm: 1.75 (s, 3H, CH3), 4.65–4.66 (d, 2H, J = 4.0 Hz, CH2), 4.98–4.99 (d, 2H, J = 4.0 Hz, CH2), 5.76 (br, 1H), 6.94–6.97 (t, 1H, J = 8.0 Hz), 7.08–7.11 (m, 4H), 7.16–7.18 (d, 2H, J = 8.0 Hz), 7.28–7.36 (t, 2H, J = 8.0 Hz); 13C-NMR (100 MHz, CDCl3) δ in ppm: 27.7, 43.0, 84.2, 117.8, 118.2, 121.1, 126.2, 129.5, 139.1, 141.6, 143.4.
2,4-difluoro-N-(4-(3-methyloxetan-3-yl)phenyl)aniline (19b): Brown solid. 71% yield. HPLC: 7.689 min (100%). ESI-MS: Calculated: 275.1 for C16H15F2NO. Found: 274.0 [M − H]−. 1H-NMR (200 MHz, CDCl3) δ in ppm: 1.73 (s, 3H), 4.62 (d, 2H, J = 6.0 Hz), 4.94 (d, 2H, J = 6.0 Hz), 6.75–6.95 (m, 2H), 6.99 (d, 2H, J = 10 Hz), 7.14 (d, 2H, J = 8.0 Hz), 7.23–7.28 (d, 1H); 13C-NMR (50 MHz, CDCl3) δ in ppm: 27.7, 42.9, 84.1, 103.9 (dd, J1 = 23.5 Hz, J2 = 23.5 Hz), 110.8 (dd, J1 = 3.8 Hz, J2 = 3.8 Hz), 117.9, 119.3 (dd, J1 = 3.4 Hz, J2 = 3.3 Hz), 126.3, 127.8 (dd, J1 = 3.4 Hz, J2 = 3.1 Hz), 139.6, 141.2, 150.9 (d, J = 11.9 Hz), 154.5 (d, J = 11.1 Hz), 155.8 (d, J = 11.7 Hz), 159.3 (d, J = 11.1 Hz).
N-(4-(3-methyloxetan-3-yl)phenyl)-2-(trifluoromethyl)aniline (19c): White solid. 88% yield. HPLC: 9.306 min (100%). ESI-MS: Calculated: 307.1 for C17H16F3NO. Found: 306.0 [M − H]−. 1H-NMR (400 MHz, CDCl3) δ in ppm: 1.78 (s, 3H, CH3), 4.67–4.70 (d, 2H, J = 6.0 Hz, CH2), 4.99–5.02 (d, 2H, J = 6.0 Hz, CH2), 6.10 (br, 1H), 6.94–7.02 (t, 1H, J = 8.0 Hz), 7.13–7.25 (q, 4H), 7.30–7.41 (m, 2H), 7.59–7.63 (d, 2H, J = 8.0 Hz); 13C-NMR (100 MHz, CDCl3) δ in ppm: 27.7, 43.1, 84.0, 114.3, 117.7, 119.8, 120.7, 126.4, 127.1, 132.8, 140.0, 140.7, 141.1, 142.4.
2-methoxy-N-(4-(3-methyloxetan-3-yl)phenyl)aniline (19d): Yellow solid. 81% yield. HPLC: 8.251 min (98%). EI-MS: Calculated: 269.1 for C17H19NO2. Found: 269.1. 1H-NMR (400 MHz, CDCl3) δ in ppm: 1.73 (s, 3H, CH3), 3.90 (s, 3H, OCH3), 4.62–4.64 (d, 2H, J = 8.0 Hz, CH2), 4.96–4.97 (d, 2H, J = 4.0 Hz, CH2), 6.85–6.90 (m, 3H), 7.15 (s, 4H), 7.27–7.29 (d, 1H); 13C-NMR (100 MHz, CDCl3) δ in ppm: 27.7, 43.0, 55.7, 84.2, 110.7, 114.7, 118.9, 120.0, 120.9, 126.1, 133.2, 139.2, 141.2, 148.4.

3.12. General Procedure L—Buchwald–Hartwig Reaction via Triflates—Benzyl Ether Deprotection

A mixture of aryl triflate, amine, Cs2CO3 as the base, BINAP as the ligand and Pd(OAc)2 as the catalyst in dry 1,4-dioxane and absolute tert-butanol (4:1) (0.03 M) was stirred at 110 °C under an atmosphere of argon. After controlling through TLC and HPLC, the mixture was allowed to cool to room temperature. It was diluted with water and subsequently extracted with ethyl acetate. The extracts were combined, washed with brine and afterwards dried over Na2SO4. The solvent was removed under vacuum, and the residue was purified by column chromatography, affording the product. Adapted from Åhman and Buchwald [33].
Then the benzyl ether deprotection was performed as follows: 0.6 eq. of palladium on carbon (10% w/w) was added to a solution of oxetane in ethanol/acetonitrile. The reaction mixture was stirred under an atmosphere of hydrogen at 25 °C until HPLC analysis indicated the end of reaction. The reaction mixture was filtered through celite, washed through with ethanol and then concentrated in vacuum to afford the final oxetane. Adapted from Croft et al. [28].
4-(3-(4-(phenylamino)phenyl)oxetan-3-yl)phenol (20a): White solid. 85% yield. HPLC: 7.618 min (96%). ESI-MS: Calculated: 317.1 for C21H19NO2. Found: 316.2 [M − H]−. 1H-NMR (400 MHz, d-acetone) δ in ppm: 5.13 (s, 4H), 6.82–6.85 (t, 3H), 7.10–7.17 (m, 8H), 7.20–7.24 (t, 2H), 7.41 (br, 1H); 13C-NMR (100 MHz, d-acetone) δ in ppm: 51.3, 84.9, 116.1, 117.9, 118.1, 120.9, 128.0, 129.9, 138.5, 139.5, 142.9, 144.7, 156.7.
4-(3-(4-((2,4-difluorophenyl)amino)phenyl)oxetan-3-yl)phenol (20b): Brown solid. 66% yield. HPLC: 7.930 min (98%). ESI-MS: Calculated: 353.1 for C21H17F2NO2. Found: 352.0 [M − H]−. 1H-NMR (400 MHz, d-acetone) δ in ppm: 5.12 (s, 4H), 6.81–6.83 (d, 2H, J = 8.0 Hz), 6.90–6.95 (t, 1H), 7.0–7.02 (d, 2H, J = 8.0 Hz), 7.11–7.13 (d, 2H, J = 8.0 Hz), 7.15–7.17 (d, 2H, J = 8.0 Hz), 7.32–7.38 (m, 1H), 8.29 (br, 1H); 13C-NMR (100 MHz, d-acetone) δ in ppm: 51.6, 85.0, 104.9, 105.1 (d, J = 3.0 Hz), 105.4, 111.9 (d, J = 4.0 Hz), 112.1 (d, J = 4.0 Hz), 116.3, 117.9, 122.1 (d, J = 3.0 Hz), 122.2 (d, J = 3.0 Hz), 128.3, 128.5, 138.7, 140.0, 143.3, 156.9.
4-(3-(4-((4-(trifluoromethyl)phenyl)amino)phenyl)oxetan-3-yl)phenol (20c): White solid. 71% yield. HPLC: 7.967 min (96%). ESI-MS: Calculated: 385.1 for C22H18F3NO2. Found: 383.9 [M − H]−. 1H-NMR (200 MHz, d-acetone) δ in ppm: 5.15 (s, 4H), 6.82–6.86 (d, 2H, J = 8.0 Hz), 7.11–7.29 (m, 8H), 7.49–7.53 (d, 2H, J = 8.0 Hz), 7.93 (br, 1H), 8.34 (br, 1H); 13C-NMR (50 MHz, d-acetone) δ in ppm: 51.5, 84.8, 115.7, 116.1, 120.5, 121.0, 127.3, 127.4, 128.2, 128.4, 138.3, 140.9, 141.8, 148.8, 156.8.
4-(3-(4-((4-methoxyphenyl)amino)phenyl)oxetan-3-yl)phenol (20d): Yellow solid. 54% yield. HPLC: 7.159 min (99%). ESI-MS: Calculated: 347.1 for C22H21NO3. Found: 345.9 [M − H]−. 1H-NMR (400 MHz, d-acetone) δ in ppm: 3.75 (s, 3H), 5.11 (s, 4H), 6.80–6.89 (t, 4H), 6.93–6.97 (d, 2H, J = 8.0 Hz), 7.07–7.13 (m, 7H); 13C-NMR (100 MHz, d-acetone) δ in ppm: 27.7, 43.0, 84.2, 117.8, 118.2, 121.1, 126.2, 129.5, 139.1, 141.6, 143.4.
4-((4-(3-(4-hydroxyphenyl)oxetan-3-yl)phenyl)amino)benzonitrile (20e): Yellow solid. 70% yield. HPLC: 6.883 min (96%). ESI-MS: Calculated: 342.1 for C22H18N2O2. Found: 341.1 [M − H]−. 1H-NMR (200 MHz, d-acetone) δ in ppm: 5.15 (s, 4H), 6.81–6.86 (d, 2H, J = 10 Hz), 7.11–7.16 (d, 2H, J = 10 Hz), 7.20–7.31 (dd, 4H, J = 10 Hz, J = 8.0 Hz), 7.52–7.56 (d, 2H, J = 8.0 Hz), 8.12 (br, 1H), 8.32 (br, 1H); 13C-NMR (50 MHz, d-acetone) δ in ppm: 51.6, 84.8, 101.5, 115.7, 116.2, 120.4, 121.5, 128.4, 128.5, 134.5, 138.3, 140.1, 142.7, 149.7, 156.9.

4. Conclusions

We successfully synthesized the spiro and the methyl-phenyl oxetane scaffolds in good and reproducible yields. The hydroxyl replacement via oxyphosphonium salts proved to be a winning strategy for the synthesis of oxetanes from the aryl-alkyl diols through a cyclization reaction. Additionally, the reaction of phenol with a functionalized oxetan-3-ol was pivotal to obtain the 3,3-diaryloxetanes. Five scaffolds and novel compounds possessing different electronic properties were synthesized using the Buchwald–Hartwig reaction, which worked well for all halides and triflate derivatives.
We succeeded in finding three new hits against the CAMK1G and AAK1 through a screening in a kinase panel using the DSF method. The results indicate that it is possible to explore compounds bearing the oxetane motif in medicinal chemistry, aiming at the discovery of novel kinase inhibitor prototypes. However, some results demonstrated that the oxetane group is probably not interacting in the hinge region, which could be associated to conformational variations or to directional hydrogen bonding differences between sp2- and sp3-hybridized oxygen atoms.
As a perspective, new experiments could be carried out to determine the Kd and IC50 of the hit compounds. Furthermore, it is also possible to extensively expand the chemical space of oxetanes using other palladium-catalyzed coupling reactions, such as Sonogashira, Suzuki and Heck.
In addition to these preliminary results, new structural modifications and experiments to measure the Kd and IC50 will be carried out for a better understanding of the structure-activity relationship.

Author Contributions

Conceptualization, F.R.d.S.A. and S.L.; methodology, F.R.d.S.A. and R.M.C.; writing—original draft preparation, F.R.d.S.A. and S.L. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Brazilian agencies FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo) (2013/50724-5 and 2014/50897-0) and CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico) (465651/2014-3) and the University of Tübingen.

Acknowledgments

The present work was possible with financial support of the Brazilian National Council for Scientific and Technological Development (CNPq) and of the University of Tübingen. The authors also thank Gerd Helms for some NMR experiments and Paulo Godoi for the Kinase experiments at the Structural Genomics Consortium—SGC (Campinas, Brazil). The authors thank Kristine Schmidt for proof-reading (language) of the manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

TDAPTris(dimethylamino)phosphine
ATPAdenosine triphosphate
BINAP2,2′-bis(diphenylphosphino)-1,1′-binaphthyl
Bu4NPF6Tetrabutylammonium hexafluorophosphate
(CH3)3SITrimethylsulfonium iodide
Li(NTf2)Lithium bis(trifluoromethanesulfonimide)
Ph3PMeIMethyltriphenylphosphonium iodide
XPhos2-Dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl

References

  1. Bull, J.A.; Croft, R.A.; Davis, O.A.; Doran, R.; Morgan, K.F. Oxetanes: Recent Advances in Synthesis, Reactivity, and Medicinal Chemistry. Chem. Rev. 2016, 116, 12150–12233. [Google Scholar] [CrossRef] [Green Version]
  2. Berthelot, M.; Besseau, F.; Laurence, C. The Hydrogen-Bond Basicity pKHB Scale of Peroxides and Ethers. Eur. J. Org. Chem. 1998, 5, 925–931. [Google Scholar] [CrossRef]
  3. Besseau, F.; Luçon, M.; Laurence, C.; Berthelot, M. Hydrogen-Bond Basicity pKHB Scale of Aldehydes and Ketones. J. Chem. Soc. Perkin Trans. 1998, 2, 101–108. [Google Scholar] [CrossRef]
  4. Wuitschik, G.; Carreira, E.M.; Wagner, B.; Fischer, H.; Parrilla, I.; Schuler, F.; Rogers-Evans, M.; Müller, K. Oxetanes in Drug Discovery: Structural and Synthetic Insights. J. Med. Chem. 2010, 53, 3227–3246. [Google Scholar] [CrossRef]
  5. Wuitschik, G.; Rogers-Evans, M.; Buckl, A.; Bernasconi, M.; Märki, M.; Godel, T.; Fischer, H.; Wagner, B.; Parrilla, I.; Schuler, F.; et al. Spirocyclic Oxetanes: Synthesis and Properties. Angew. Chem. 2008, 120, 4588–4591. [Google Scholar] [CrossRef]
  6. Burkhard, J.A.; Wuitschik, G.; Plancher, J.-M.; Rogers-Evans, M.; Carreira, E.M. Synthesis and Stability of Oxetane Analogs of Thalidomide and Lenalidomide. Org. Lett. 2013, 15, 4312–4315. [Google Scholar] [CrossRef]
  7. Rogers-Evans, M.; Knust, H.; Plancher, J.-M.; Carreira, E.M.; Wuitschik, G.; Burkhard, J.; Dong, B.; Carine, G. Adventures in Drug-like Chemistry Space: From Oxetanes to Spiroazetidines and Beyond! Chim. Int. J. Chem. 2014, 68, 492–499. [Google Scholar] [CrossRef]
  8. Davis, O.A.; Bull, J.A. Recent Advances in the Synthesis of 2-Substituted Oxetanes. Synlett 2015, 26, 1283–1288. [Google Scholar] [CrossRef] [Green Version]
  9. Davis, O.A.; Croft, R.A.; Bull, J.A. Synthesis of diversely functionalised 2,2-disubstituted oxetanes: Fragment motifs in new chemical space. Chem. Commun. 2015, 51, 15446. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  10. Morgan, K.F.; Hollingsworth, I.A.; Bull, J.A. 2-(Aryl-Sulfonyl)oxetanes as Designer 3-Dimensional Fragments for Fragment Screening: Synthesis and Strategies for Functionalisation. Chem. Commun. 2014, 50, 5203–5205. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Blomgren, P.; Chandrasekhar, J.; Di Paolo, J.A.; Fung, W.; Geng, G.; Ip, C.; Jones, R.; Kropf, J.E.; Lansdon, E.B.; Lee, S.; et al. Discovery of Lanraplenib (GS-9876), a Once—Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases. ACS Med. Chem. Lett. 2020, 11, 506–513. [Google Scholar] [CrossRef] [PubMed]
  12. Silverman, R.B.; Holladay, M.W. Lead Discovery and Lead Modification. In The Organic Chemistry of Drug Design and Drug Action; Academic Press: Boston, MA, USA, 2014; pp. 19–122. [Google Scholar]
  13. Akritopoulou-Zanze, I.; Hajduk, P.J. Kinase-Targeted Libraries: The Design and Synthesis of Novel, Potent, and Selective Kinase Inhibitors. Drug Discov. Today 2009, 14, 291–297. [Google Scholar] [CrossRef] [PubMed]
  14. Searles, S.; Pollart, K.A.; Block, F. Oxetanes. VII. Synthesis from 1,3-Diols. Reactions of Oxetanes and of 1,3-Butanediol with Hydrogen Chloride, Hydrogen Bromide and Acetyl Chloride 1,2. J. Am. Chem. Soc. 1957, 79, 952–956. [Google Scholar] [CrossRef]
  15. Picard, P.; Leclercq, D.; Bats, J.-P.; Moulines, J. An Efficient One-Pot Synthesis of Oxetanes from 1,3-Diols. Synthesis 1981, 550–551. [Google Scholar] [CrossRef]
  16. Searles, S.; Nickerson, R.G.; Witsiepe, W.K. Oxetanes. IX. Structural and Solvent Effects in the Reaction of γ-Bromoalcohols with Base 1,2. J. Org. Chem. 1959, 24, 1839–1844. [Google Scholar] [CrossRef]
  17. Grob, C.A.; Schiess, P.W. Heterolytic Fragmentation. A Class of Organic Reactions. Angew. Chem. Int. Ed. Engl. 1967, 6, 1–15. [Google Scholar] [CrossRef]
  18. Grob, C.A. Mechanisms and Stereochemistry of Heterolytic Fragmentation. Angew. Chem. Int. Ed. Engl. 1969, 8, 535–546. [Google Scholar] [CrossRef]
  19. Winter, B. Spirocyclic Ethers Related to Ambrox®: Synthesis and Structure-Odor Relationships. Helv. Chim. Acta 2004, 87, 1616–1627. [Google Scholar] [CrossRef]
  20. Snyder, S.E.; Aviles-Garay, F.A.; Chakraborti, R.; Nichols, D.E.; Watts, V.J.; Mailman, R.B. Synthesis and Evaluation of 6,7-Dihydroxy-2,3,4,8,9,13b-Hexahydro-1H- benzo[6,7]cyclohepta[1,2,3-ef][3]benzazepine,6,7-Dihydroxy-1,2,3,4,8,12b-hexahydroanthr[10,4a,4-Cd]azepine, and 10-(Aminomethyl)-9,10-Dihydro-1,2-Dihydroxyanthracene as Conformationally Restricted Analogs of Beta-Phenyldopamine. J. Med. Chem. 1995, 38, 2395–2409. [Google Scholar] [CrossRef]
  21. Sato, T.; Onuma, T.; Nakamura, I.; Terada, M. Platinum-Catalyzed Cycloisomerization of 1,4-Enynes via 1,2-Alkenyl Rearrangement. Org. Lett. 2011, 13, 4992–4995. [Google Scholar] [CrossRef]
  22. Castro, B.R. Replacement of Alcoholic Hydroxyl Groups by Halogens and Other Nucleophiles via Oxyphosphonium Intermediates. Org. React. 2005, 29, 1–162. [Google Scholar] [CrossRef]
  23. Castro, B.; Selve, C. Sels D’alkyloxyphosphonium. VI—Nouvelle Preparation Des Dialkyl-3,3 Oxetannes. Tetrahedron Lett. 1973, 14, 4459–4460. [Google Scholar] [CrossRef]
  24. Liwosz, T.W.; Chemler, S.R. Copper-Catalyzed Oxidative Amination and Allylic Amination of Alkenes. Chem. Eur. J. 2013, 19, 12771–12777. [Google Scholar] [CrossRef] [Green Version]
  25. Brown, H.C.; Rao, B.C.S. A New Technique for the Conversion of Olefins into Organoboranes and Related Alcohols. J. Am. Chem. Soc. 1956, 78, 5694–5695. [Google Scholar] [CrossRef]
  26. Zimmerman, H.E.; Nesterov, E.E. Quantitative Cavities and Reactivity in Stages of Crystal Lattices:  Mechanistic and Exploratory Organic Photochemistry. J. Am. Chem. Soc. 2002, 124, 2818–2830. [Google Scholar] [CrossRef]
  27. Thongsornkleeb, C.; Danheiser, R.L. A Practical Method for the Synthesis of 2-Alkynylpropenals. J. Org. Chem. 2005, 70, 2364–2367. [Google Scholar] [CrossRef]
  28. Croft, R.A.; Mousseau, J.J.; Choi, C.; Bull, J.A. Structurally Divergent Lithium Catalyzed Friedel–Crafts Reactions on Oxetan-3-Ols: Synthesis of 3,3-Diaryloxetanes and 2,3-Dihydrobenzofurans. Chem. Eur. J. 2016, 22, 16271–16276. [Google Scholar] [CrossRef] [Green Version]
  29. Chen, L.; Yin, X.-P.; Wang, C.-H.; Zhou, J. Catalytic Functionalization of Tertiary Alcohols to Fully Substituted Carbon Centres. Org. Biomol. Chem. 2014, 12, 6033–6048. [Google Scholar] [CrossRef]
  30. Thompson, A.L.S.; Kabalka, G.W.; Akula, M.R.; Huffman, J.W. The Conversion of Phenols to the Corresponding Aryl Halides Under Mild Conditions. Synthesis 2005, 2005, 547–550. [Google Scholar] [CrossRef]
  31. Martz, K.E.; Dorn, A.; Baur, B.; Schattel, V.; Goettert, M.I.; Mayer-Wrangowski, S.C.; Rauh, D.; Laufer, S.A. Targeting the Hinge Glycine Flip and the Activation Loop: Novel Approach to Potent p38α Inhibitors. J. Med. Chem. 2012, 55, 7862–7874. [Google Scholar] [CrossRef]
  32. Wolfe, J.P.; Buchwald, S.L. Palladium-Catalyzed Amination of Aryl Triflates. J. Org. Chem. 1997, 62, 1264–1267. [Google Scholar] [CrossRef]
  33. Åhman, J.; Buchwald, S.L. An Improved Method for the Palladium-Catalyzed Amination of Aryl Triflates. Tetrahedron Lett. 1997, 38, 6363–6366. [Google Scholar] [CrossRef]
  34. Koeberle, S.C.; Fischer, S.; Schollmeyer, D.; Schattel, V.; Grütter, C.; Rauh, D.; Laufer, S.A. Design, Synthesis, and Biological Evaluation of Novel Disubstituted Dibenzosuberones as Highly Potent and Selective Inhibitors of p38 Mitogen Activated Protein Kinase. J. Med. Chem. 2012, 55, 5868–5877. [Google Scholar] [CrossRef] [PubMed]
  35. Niesen, F.H.; Berglund, H.; Vedadi, M. The Use of Differential Scanning Fluorimetry to Detect Ligand Interactions That Promote Protein Stability. Nat. Protoc. 2007, 2, 2212–2221. [Google Scholar] [CrossRef]
  36. Huynh, K.; Partch, C.L. Analysis of Protein Stability and Ligand Interactions by Thermal Shift Assay. Curr. Protoc. Protein Sci. 2015, 79, 28.9.1–28.9.14. [Google Scholar] [CrossRef]
  37. Shen, H.; Hu, Y.; Zhang, Y.; Zhou, X.; Xu, Z. Calcium–calmodulin Dependent Protein Kinase I from Macrobrachium Nipponense: cDNA Cloning and Involvement in Molting. Gene 2014, 538, 235–243. [Google Scholar] [CrossRef]
  38. Louis, J.V.; Lu, Y.; Pieschl, R.; Tian, Y.; Hong, Y.; Dandapani, K.; Naidu, S.; Vikramadithyan, R.K.; Dzierba, C.; Sarvasiddhi, S.K.; et al. [3H]BMT-046091 a Potent and Selective Radioligand to Determine AAK1 Distribution and Target Engagement. Neuropharmacology 2017, 118, 167–174. [Google Scholar] [CrossRef]
  39. Kostich, W.; Hamman, B.D.; Li, Y.-W.; Naidu, S.; Dandapani, K.; Feng, J.; Easton, A.; Bourin, C.; Baker, K.; Allen, J.; et al. Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain. J. Pharmacol. Exp. Ther. 2016, 358, 371–386. [Google Scholar] [CrossRef] [Green Version]
  40. Neveu, G.; Ziv-Av, A.; Barouch-Bentov, R.; Berkerman, E.; Mulholland, J.; Einav, S. AP2-Associated Protein Kinase 1 and Cyclin G-Associated Kinase Regulate Hepatitis C Virus Entry and Are Potential Drug Targets. J. Virol. 2015, 89, 4387–4404. [Google Scholar] [CrossRef] [Green Version]
  41. Bekerman, E.; Neveu, G.; Shulla, A.; Brannan, J.; Pu, S.-Y.; Wang, S.; Xiao, F.; Barouch-Bentov, R.; Bakken, R.R.; Mateo, R.; et al. Anticancer Kinase Inhibitors Impair Intracellular Viral Trafficking and Exert Broad-Spectrum Antiviral Effects. J. Clin. Investig. 2017, 127, 1338–1352. [Google Scholar] [CrossRef]
Ijms 21 08199 g001 550
Figure 1. Natural products and marketed drugs containing an oxetane group.
Figure 1. Natural products and marketed drugs containing an oxetane group.
Ijms 21 08199 g001
Ijms 21 08199 g002 550
Figure 2. Schematic of the interactions of benzosuberone and oxetane analogs in the hinge region.
Figure 2. Schematic of the interactions of benzosuberone and oxetane analogs in the hinge region.
Ijms 21 08199 g002
Ijms 21 08199 g003 550
Figure 3. Design of new oxetane derivatives.
Figure 3. Design of new oxetane derivatives.
Ijms 21 08199 g003
Ijms 21 08199 g004 550
Figure 4. Strategies used to synthesize the oxetane scaffolds.
Figure 4. Strategies used to synthesize the oxetane scaffolds.
Ijms 21 08199 g004
Ijms 21 08199 sch001 550
Scheme 1. Reagents and Conditions: (i) (CH3)3SI, NaH, DMSO, r.t. (ii) ZnI2, benzene, reflux. (iii) CH2O, KOH, ethylene glycol, reflux. (iv) 1. TDAP, CCl4, THF, −40 °C; 2. NaOMe, MeOH, reflux.
Scheme 1. Reagents and Conditions: (i) (CH3)3SI, NaH, DMSO, r.t. (ii) ZnI2, benzene, reflux. (iii) CH2O, KOH, ethylene glycol, reflux. (iv) 1. TDAP, CCl4, THF, −40 °C; 2. NaOMe, MeOH, reflux.
Ijms 21 08199 sch001
Ijms 21 08199 sch002 550
Scheme 2. Reagents and Conditions: (i) 1. Ph3PMeI, t-BuOK, THF, 0 °C; 2. 5-chloro-indanone, 0 °C to r.t. (ii) 1. BH3, THF, 0 °C; 2. NaOH, H2O2, 0 °C—r.t. (iii) Dess–Martin periodinane, CH2Cl2, r.t. (iv) CH2O, KOH, ethylene glycol, reflux. (v) 1. TDAP, CCl4, THF, −40 °C; 2. NaOMe, MeOH, reflux.
Scheme 2. Reagents and Conditions: (i) 1. Ph3PMeI, t-BuOK, THF, 0 °C; 2. 5-chloro-indanone, 0 °C to r.t. (ii) 1. BH3, THF, 0 °C; 2. NaOH, H2O2, 0 °C—r.t. (iii) Dess–Martin periodinane, CH2Cl2, r.t. (iv) CH2O, KOH, ethylene glycol, reflux. (v) 1. TDAP, CCl4, THF, −40 °C; 2. NaOMe, MeOH, reflux.
Ijms 21 08199 sch002
Ijms 21 08199 sch003 550
Scheme 3. Reagents and Conditions: (i) n-BuLi, oxetan-3-one, THF, −78 °C. (ii) Li(NTf2), Bu4NPF6, CHCl3, 40 °C. (iii) triflic anhydride, pyridine, CH2Cl2, r.t.
Scheme 3. Reagents and Conditions: (i) n-BuLi, oxetan-3-one, THF, −78 °C. (ii) Li(NTf2), Bu4NPF6, CHCl3, 40 °C. (iii) triflic anhydride, pyridine, CH2Cl2, r.t.
Ijms 21 08199 sch003
Ijms 21 08199 g005 550
Figure 5. Results obtained from a kinase panel using differential scanning fluorimetry (DSF).
Figure 5. Results obtained from a kinase panel using differential scanning fluorimetry (DSF).
Ijms 21 08199 g005
Ijms 21 08199 g006 550
Figure 6. ∆Tm values obtained for the CAMK1G calcium/calmodulin dependent protein kinase I gamma.
Figure 6. ∆Tm values obtained for the CAMK1G calcium/calmodulin dependent protein kinase I gamma.
Ijms 21 08199 g006
Ijms 21 08199 g007 550
Figure 7. ∆Tm values obtained for the AAK1 AP2-associated protein kinase 1.
Figure 7. ∆Tm values obtained for the AAK1 AP2-associated protein kinase 1.
Ijms 21 08199 g007
Table
Table 1. N-arylamine oxetanes obtained via Buchwald–Hartwig Reaction.
Table 1. N-arylamine oxetanes obtained via Buchwald–Hartwig Reaction.
EntryHalide/TriflateProductYield
(%) a
1 Ijms 21 08199 i001 Ijms 21 08199 i00216a: W = H
16b: W = 2,4-di-F
16c: W = 2-CF3
16d: W = 4-OCH3		86
73
77
86
2 Ijms 21 08199 i003 Ijms 21 08199 i00417a: W = H
17b: W = 2,4-di-F
17c: W = 2-CF3
17d: W = 2-OCH3		92
51
82
82
3 Ijms 21 08199 i005 Ijms 21 08199 i00618a: W = H
18b: W = 2,4-di-F
18c: W = 2-CF3
18d: W = 2-OCH3		71
76
95
80
4 Ijms 21 08199 i007 Ijms 21 08199 i00819a: W = H
19b: W = 2,4-di-F
19c: W = 2-CF3
19d: W = 2-OCH3		83
71
88
81
5 b Ijms 21 08199 i009 Ijms 21 08199 i01020a: W = H
20b: W = 2,4-di-F
20c: W = 4-CF3
20d: W = 4-OCH3
20e: W = 4-CN		85
66
71
54
70
a Isolated yields after purification by column chromatography. b Products obtained after deprotection of benzyl ether group.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Alves, F.R.d.S.; Couñago, R.M.; Laufer, S. Chemical Space Exploration of Oxetanes. Int. J. Mol. Sci. 2020, 21, 8199. https://doi.org/10.3390/ijms21218199

AMA Style

Alves FRdS, Couñago RM, Laufer S. Chemical Space Exploration of Oxetanes. International Journal of Molecular Sciences. 2020; 21(21):8199. https://doi.org/10.3390/ijms21218199

Chicago/Turabian Style

Alves, Fernando Rodrigues de Sá, Rafael M. Couñago, and Stefan Laufer. 2020. "Chemical Space Exploration of Oxetanes" International Journal of Molecular Sciences 21, no. 21: 8199. https://doi.org/10.3390/ijms21218199

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop